An Open-Label, Pilot Study of Daratumumab SC in Mild to Moderate Alzheimer’s Disease
Journal of Alzheimer's Disease Reports · 09.01.2024 · 8 (1) · 1111-1114
DOI: 10.3233/adr-240089 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Alzheimer's Disease Reports, online erschienen am 31.07.2024. Verfasst von Marc L Gordon und 7 weiteren Autor:innen. Beteiligte Einrichtung: Northwell, NY, USA. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIA NIH HHS.
Themen: Demenz
Abstract (Originalsprache)
We conducted a small, open-label, pilot study of daratumumab to explore target engagement, safety, and potential efficacy in patients with mild to moderate Alzheimer’s disease. Daratumumab SC 1800 mg was given subcutaneously weekly for 8 weeks, then every 2 weeks for 16 weeks. Flow cytometry to measure the CD38+ proportion of CD8 + CD4- T cells and cognitive assessments were performed at baseline, day 176, and day 246. Daratumumab significantly reduced CD38 + CD8 + CD4- T cells after 24 weeks and this effect persisted 11 weeks thereafter. There was no hematological toxicity or unexpected adverse events. Responder analysis showed no improvement on cognitive outcome measures.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Northwell, NY, USA.
- Litwin-Zucker Research Center, Feinstein Institutes for Medical Research, Manhasset, NY, USA.
- Departments of Neurology and Psychiatry, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY, USA.
- Institute of Molecular Medicine, Feinstein Institutes for Medical Research, Manhasset, NY, USA.
- Institute for Neurology and Neurosurgery, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY, USA.
- Department of Psychiatry, Zucker Hillside Hospital, Northwell Health, Glen Oaks, NY, USA.
Förderung
- NIA NIH HHS
Zitieren
APA
Gordon, M. L., Christen, E., Keehlisen, L., Gong, M., Lam, F., Giliberto, L., Gomar, J. J., & Koppel, J. (2024). An Open-Label, Pilot Study of Daratumumab SC in Mild to Moderate Alzheimer’s Disease. Journal of Alzheimer's Disease Reports, 8(1), 1111-1114. https://doi.org/10.3233/adr-240089
Vancouver
Gordon ML, Christen E, Keehlisen L, Gong M, Lam F, Giliberto L, et al. An Open-Label, Pilot Study of Daratumumab SC in Mild to Moderate Alzheimer’s Disease. Journal of Alzheimer's Disease Reports. 2024;8(1):1111-1114. doi:10.3233/adr-240089
BibTeX
@article{Gordon2024,
author = {Gordon, Marc L and Christen, Erica and Keehlisen, Lynda and Gong, Michelle and Lam, Fung and Giliberto, Luca and Gomar, Jesus J and Koppel, Jeremy},
title = {An Open-Label, Pilot Study of Daratumumab SC in Mild to Moderate Alzheimer’s Disease},
journal = {Journal of Alzheimer's Disease Reports},
year = {2024},
volume = {8},
number = {1},
pages = {1111--1114},
doi = {10.3233/adr-240089}
}
EUVIMED